Karen Keeperman
About Karen Keeperman
Karen Keeperman is a Clinical Science Team Leader and Director at Bristol Myers Squibb and Celgene, with extensive experience in clinical trials and program leadership.
Company
Karen Keeperman currently holds leadership roles at two major pharmaceutical companies. She is the Clinical Science Team Leader / Director at Bristol Myers Squibb in Summit, New Jersey. She also serves as the Program Director Clinical Science Lead (CarT) at Celgene, located in the same city. Both positions involve overseeing clinical science initiatives, with a particular focus on CarT, a key area of research and development in modern oncology.
Title
Karen Keeperman holds the titles of Clinical Science Team Leader / Director and Program Director Clinical Science Lead (CarT). Her responsibilities involve leading strategic clinical science initiatives, managing clinical trial programs, and overseeing scientific messaging and narrative processes for various clinical submissions. Her roles are critical in the successful development and market approval of pharmaceutical assets.
Education and Expertise
Karen Keeperman pursued her education rigorously, earning a Master of Public Administration in Healthcare Administration from LIU-Old Brookville and a Bachelor of Science in Biology and Psychology from Stony Brook University. This educational background laid a strong foundation for her expertise in clinical science and healthcare administration, enabling her to excel in leading clinical trial teams and managing complex medical projects.
Professional Background
Karen Keeperman has a comprehensive professional background in the pharmaceutical and clinical research industries, spanning multiple high-profile organizations. She worked at Pfizer as Clinician / Non-MD / Director from 2015 to 2019, Novartis as Sr. Clinical Trial Head from 2012 to 2015, and had an extensive tenure at Roche Pharmaceuticals from 1999 to 2012 in various roles including Senior Global Studies Leader / Associate Director. Earlier in her career, she gained experience at Research Testing Laboratories and Memorial Sloan Kettering Cancer Center, which provided her with a solid foundation in clinical research.
Key Achievements
Karen Keeperman has led clinical science teams in the successful market approval of major pharmaceutical assets such as Inrebic, Rebloyzl, and Breyanzi. She played an essential role in the Liso-Cel Biologics License Application (BLA) submission for US approval, including strategic messaging and clinical narrative review. Additionally, she created a process for incorporating transgene assay results into the Liso-Cel BLA submission and developed asset-specific training sessions. Her contributions also extend to the Onureg EU submission and overseeing clinical quality control processes.